[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

chencha3 wrote:

@adam-smnk @joker-eph Merged #86594, and recreate it againt the main branch. 
#88973 

https://github.com/llvm/llvm-project/pull/88439
___
llvm-branch-commits mailing list
llvm-branch-commits@lists.llvm.org
https://lists.llvm.org/cgi-bin/mailman/listinfo/llvm-branch-commits

[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 updated 
https://github.com/llvm/llvm-project/pull/88439

>From 6021411059863c9a2bfdfc91e35628328e709a8c Mon Sep 17 00:00:00 2001
From: Chao Chen 
Date: Thu, 11 Apr 2024 15:46:26 -0500
Subject: [PATCH 1/6] Add dpas and named barrier ops

---
 .../mlir/Dialect/XeGPU/IR/CMakeLists.txt  |   6 +-
 mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h|   3 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUAttrs.td   |   1 +
 .../mlir/Dialect/XeGPU/IR/XeGPUDialect.td |   4 +-
 .../include/mlir/Dialect/XeGPU/IR/XeGPUOps.td | 154 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUTypes.td   |  11 ++
 mlir/lib/Dialect/XeGPU/IR/XeGPUOps.cpp|  23 +++
 mlir/test/Dialect/XeGPU/XeGPUOps.mlir |  57 ++-
 8 files changed, 250 insertions(+), 9 deletions(-)

diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt 
b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
index f1740e9ed929a6..3f8cac4dc07c3c 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
@@ -2,12 +2,12 @@ add_mlir_dialect(XeGPU xegpu)
 add_mlir_doc(XeGPU XeGPU Dialects/ -gen-dialect-doc -dialect=xegpu)
 
 set(LLVM_TARGET_DEFINITIONS XeGPU.td)
-mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls)
-mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs)
+mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls -attrdefs-dialect=xegpu)
+mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs -attrdefs-dialect=xegpu)
 add_public_tablegen_target(MLIRXeGPUAttrsIncGen)
 add_dependencies(mlir-headers MLIRXeGPUAttrsIncGen)
 
-set(LLVM_TARGET_DEFINITIONS XeGPU.td)
+set(LLVM_TARGET_DEFINITIONS XeGPUAttrs.td)
 mlir_tablegen(XeGPUEnums.h.inc -gen-enum-decls)
 mlir_tablegen(XeGPUEnums.cpp.inc -gen-enum-defs)
 add_public_tablegen_target(MLIRXeGPUEnumsIncGen)
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
index eca9255ff3974b..7ac0cf77fe59bb 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPU_H
 
 #include "mlir/Bytecode/BytecodeOpInterface.h"
+#include "mlir/Dialect/Arith/IR/Arith.h"
 #include "mlir/IR/BuiltinTypes.h"
 #include "mlir/IR/Dialect.h"
 #include "mlir/IR/TypeUtilities.h"
@@ -19,7 +20,7 @@
 
 namespace mlir {
 namespace xegpu {
-// placeholder
+class TensorDescType;
 } // namespace xegpu
 } // namespace mlir
 
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
index 6579d07ec26215..c14cba4990a738 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPUATTRS_TD
 
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
+include "mlir/IR/AttrTypeBase.td"
 include "mlir/IR/EnumAttr.td"
 
 class XeGPUAttr traits = [],
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
index c2f09319c790e0..765f218f95d269 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
@@ -17,12 +17,14 @@ def XeGPU_Dialect : Dialect {
 let summary = "The XeGPU dialect that models Intel GPU's ISA";
 let description = [{
   The XeGPU dialect models Intel Xe ISA semantics but works at vector and
-  TensorDesc data type. It provides 1:1 mappings to match Xe instructions 
+  TensorDesc data type. It provides 1:1 mappings to match Xe instructions
   like DPAS and 2D block load. The matrix size being processed at this 
level
   exactly matches the hardware instructions or the intrinsic supported by
   the lower-level GPU compiler.
 }];
 
+let dependentDialects = ["arith::ArithDialect"];
+
 let useDefaultTypePrinterParser = true;
 let useDefaultAttributePrinterParser = true;
 }
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
index a031a75984a536..3423609b76c706 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
@@ -9,7 +9,7 @@
 #ifndef MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 #define MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 
-include "mlir/IR/AttrTypeBase.td"
+include "mlir/Dialect/Arith/IR/ArithBase.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUAttrs.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUTypes.td"
@@ -35,7 +35,7 @@ class XeGPU_Op traits = []>:
 
 static ::mlir::ParseResult parseProperties(::mlir::OpAsmParser ,
  ::mlir::OperationState ) {
-  if (mlir::succeeded(parser.parseLess())) {
+  if (mlir::succeeded(parser.parseOptionalLess())) {
 

[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 updated 
https://github.com/llvm/llvm-project/pull/88439

>From 6021411059863c9a2bfdfc91e35628328e709a8c Mon Sep 17 00:00:00 2001
From: Chao Chen 
Date: Thu, 11 Apr 2024 15:46:26 -0500
Subject: [PATCH 1/5] Add dpas and named barrier ops

---
 .../mlir/Dialect/XeGPU/IR/CMakeLists.txt  |   6 +-
 mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h|   3 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUAttrs.td   |   1 +
 .../mlir/Dialect/XeGPU/IR/XeGPUDialect.td |   4 +-
 .../include/mlir/Dialect/XeGPU/IR/XeGPUOps.td | 154 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUTypes.td   |  11 ++
 mlir/lib/Dialect/XeGPU/IR/XeGPUOps.cpp|  23 +++
 mlir/test/Dialect/XeGPU/XeGPUOps.mlir |  57 ++-
 8 files changed, 250 insertions(+), 9 deletions(-)

diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt 
b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
index f1740e9ed929a6..3f8cac4dc07c3c 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
@@ -2,12 +2,12 @@ add_mlir_dialect(XeGPU xegpu)
 add_mlir_doc(XeGPU XeGPU Dialects/ -gen-dialect-doc -dialect=xegpu)
 
 set(LLVM_TARGET_DEFINITIONS XeGPU.td)
-mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls)
-mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs)
+mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls -attrdefs-dialect=xegpu)
+mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs -attrdefs-dialect=xegpu)
 add_public_tablegen_target(MLIRXeGPUAttrsIncGen)
 add_dependencies(mlir-headers MLIRXeGPUAttrsIncGen)
 
-set(LLVM_TARGET_DEFINITIONS XeGPU.td)
+set(LLVM_TARGET_DEFINITIONS XeGPUAttrs.td)
 mlir_tablegen(XeGPUEnums.h.inc -gen-enum-decls)
 mlir_tablegen(XeGPUEnums.cpp.inc -gen-enum-defs)
 add_public_tablegen_target(MLIRXeGPUEnumsIncGen)
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
index eca9255ff3974b..7ac0cf77fe59bb 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPU_H
 
 #include "mlir/Bytecode/BytecodeOpInterface.h"
+#include "mlir/Dialect/Arith/IR/Arith.h"
 #include "mlir/IR/BuiltinTypes.h"
 #include "mlir/IR/Dialect.h"
 #include "mlir/IR/TypeUtilities.h"
@@ -19,7 +20,7 @@
 
 namespace mlir {
 namespace xegpu {
-// placeholder
+class TensorDescType;
 } // namespace xegpu
 } // namespace mlir
 
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
index 6579d07ec26215..c14cba4990a738 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPUATTRS_TD
 
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
+include "mlir/IR/AttrTypeBase.td"
 include "mlir/IR/EnumAttr.td"
 
 class XeGPUAttr traits = [],
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
index c2f09319c790e0..765f218f95d269 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
@@ -17,12 +17,14 @@ def XeGPU_Dialect : Dialect {
 let summary = "The XeGPU dialect that models Intel GPU's ISA";
 let description = [{
   The XeGPU dialect models Intel Xe ISA semantics but works at vector and
-  TensorDesc data type. It provides 1:1 mappings to match Xe instructions 
+  TensorDesc data type. It provides 1:1 mappings to match Xe instructions
   like DPAS and 2D block load. The matrix size being processed at this 
level
   exactly matches the hardware instructions or the intrinsic supported by
   the lower-level GPU compiler.
 }];
 
+let dependentDialects = ["arith::ArithDialect"];
+
 let useDefaultTypePrinterParser = true;
 let useDefaultAttributePrinterParser = true;
 }
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
index a031a75984a536..3423609b76c706 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
@@ -9,7 +9,7 @@
 #ifndef MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 #define MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 
-include "mlir/IR/AttrTypeBase.td"
+include "mlir/Dialect/Arith/IR/ArithBase.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUAttrs.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUTypes.td"
@@ -35,7 +35,7 @@ class XeGPU_Op traits = []>:
 
 static ::mlir::ParseResult parseProperties(::mlir::OpAsmParser ,
  ::mlir::OperationState ) {
-  if (mlir::succeeded(parser.parseLess())) {
+  if (mlir::succeeded(parser.parseOptionalLess())) {
 

[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 updated 
https://github.com/llvm/llvm-project/pull/88439

>From 6021411059863c9a2bfdfc91e35628328e709a8c Mon Sep 17 00:00:00 2001
From: Chao Chen 
Date: Thu, 11 Apr 2024 15:46:26 -0500
Subject: [PATCH 1/4] Add dpas and named barrier ops

---
 .../mlir/Dialect/XeGPU/IR/CMakeLists.txt  |   6 +-
 mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h|   3 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUAttrs.td   |   1 +
 .../mlir/Dialect/XeGPU/IR/XeGPUDialect.td |   4 +-
 .../include/mlir/Dialect/XeGPU/IR/XeGPUOps.td | 154 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUTypes.td   |  11 ++
 mlir/lib/Dialect/XeGPU/IR/XeGPUOps.cpp|  23 +++
 mlir/test/Dialect/XeGPU/XeGPUOps.mlir |  57 ++-
 8 files changed, 250 insertions(+), 9 deletions(-)

diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt 
b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
index f1740e9ed929a6..3f8cac4dc07c3c 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
@@ -2,12 +2,12 @@ add_mlir_dialect(XeGPU xegpu)
 add_mlir_doc(XeGPU XeGPU Dialects/ -gen-dialect-doc -dialect=xegpu)
 
 set(LLVM_TARGET_DEFINITIONS XeGPU.td)
-mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls)
-mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs)
+mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls -attrdefs-dialect=xegpu)
+mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs -attrdefs-dialect=xegpu)
 add_public_tablegen_target(MLIRXeGPUAttrsIncGen)
 add_dependencies(mlir-headers MLIRXeGPUAttrsIncGen)
 
-set(LLVM_TARGET_DEFINITIONS XeGPU.td)
+set(LLVM_TARGET_DEFINITIONS XeGPUAttrs.td)
 mlir_tablegen(XeGPUEnums.h.inc -gen-enum-decls)
 mlir_tablegen(XeGPUEnums.cpp.inc -gen-enum-defs)
 add_public_tablegen_target(MLIRXeGPUEnumsIncGen)
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
index eca9255ff3974b..7ac0cf77fe59bb 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPU_H
 
 #include "mlir/Bytecode/BytecodeOpInterface.h"
+#include "mlir/Dialect/Arith/IR/Arith.h"
 #include "mlir/IR/BuiltinTypes.h"
 #include "mlir/IR/Dialect.h"
 #include "mlir/IR/TypeUtilities.h"
@@ -19,7 +20,7 @@
 
 namespace mlir {
 namespace xegpu {
-// placeholder
+class TensorDescType;
 } // namespace xegpu
 } // namespace mlir
 
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
index 6579d07ec26215..c14cba4990a738 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPUATTRS_TD
 
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
+include "mlir/IR/AttrTypeBase.td"
 include "mlir/IR/EnumAttr.td"
 
 class XeGPUAttr traits = [],
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
index c2f09319c790e0..765f218f95d269 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
@@ -17,12 +17,14 @@ def XeGPU_Dialect : Dialect {
 let summary = "The XeGPU dialect that models Intel GPU's ISA";
 let description = [{
   The XeGPU dialect models Intel Xe ISA semantics but works at vector and
-  TensorDesc data type. It provides 1:1 mappings to match Xe instructions 
+  TensorDesc data type. It provides 1:1 mappings to match Xe instructions
   like DPAS and 2D block load. The matrix size being processed at this 
level
   exactly matches the hardware instructions or the intrinsic supported by
   the lower-level GPU compiler.
 }];
 
+let dependentDialects = ["arith::ArithDialect"];
+
 let useDefaultTypePrinterParser = true;
 let useDefaultAttributePrinterParser = true;
 }
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
index a031a75984a536..3423609b76c706 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
@@ -9,7 +9,7 @@
 #ifndef MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 #define MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 
-include "mlir/IR/AttrTypeBase.td"
+include "mlir/Dialect/Arith/IR/ArithBase.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUAttrs.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUTypes.td"
@@ -35,7 +35,7 @@ class XeGPU_Op traits = []>:
 
 static ::mlir::ParseResult parseProperties(::mlir::OpAsmParser ,
  ::mlir::OperationState ) {
-  if (mlir::succeeded(parser.parseLess())) {
+  if (mlir::succeeded(parser.parseOptionalLess())) {
 

[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 updated 
https://github.com/llvm/llvm-project/pull/88439

>From 6021411059863c9a2bfdfc91e35628328e709a8c Mon Sep 17 00:00:00 2001
From: Chao Chen 
Date: Thu, 11 Apr 2024 15:46:26 -0500
Subject: [PATCH 1/3] Add dpas and named barrier ops

---
 .../mlir/Dialect/XeGPU/IR/CMakeLists.txt  |   6 +-
 mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h|   3 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUAttrs.td   |   1 +
 .../mlir/Dialect/XeGPU/IR/XeGPUDialect.td |   4 +-
 .../include/mlir/Dialect/XeGPU/IR/XeGPUOps.td | 154 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUTypes.td   |  11 ++
 mlir/lib/Dialect/XeGPU/IR/XeGPUOps.cpp|  23 +++
 mlir/test/Dialect/XeGPU/XeGPUOps.mlir |  57 ++-
 8 files changed, 250 insertions(+), 9 deletions(-)

diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt 
b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
index f1740e9ed929a6..3f8cac4dc07c3c 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
@@ -2,12 +2,12 @@ add_mlir_dialect(XeGPU xegpu)
 add_mlir_doc(XeGPU XeGPU Dialects/ -gen-dialect-doc -dialect=xegpu)
 
 set(LLVM_TARGET_DEFINITIONS XeGPU.td)
-mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls)
-mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs)
+mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls -attrdefs-dialect=xegpu)
+mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs -attrdefs-dialect=xegpu)
 add_public_tablegen_target(MLIRXeGPUAttrsIncGen)
 add_dependencies(mlir-headers MLIRXeGPUAttrsIncGen)
 
-set(LLVM_TARGET_DEFINITIONS XeGPU.td)
+set(LLVM_TARGET_DEFINITIONS XeGPUAttrs.td)
 mlir_tablegen(XeGPUEnums.h.inc -gen-enum-decls)
 mlir_tablegen(XeGPUEnums.cpp.inc -gen-enum-defs)
 add_public_tablegen_target(MLIRXeGPUEnumsIncGen)
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
index eca9255ff3974b..7ac0cf77fe59bb 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPU_H
 
 #include "mlir/Bytecode/BytecodeOpInterface.h"
+#include "mlir/Dialect/Arith/IR/Arith.h"
 #include "mlir/IR/BuiltinTypes.h"
 #include "mlir/IR/Dialect.h"
 #include "mlir/IR/TypeUtilities.h"
@@ -19,7 +20,7 @@
 
 namespace mlir {
 namespace xegpu {
-// placeholder
+class TensorDescType;
 } // namespace xegpu
 } // namespace mlir
 
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
index 6579d07ec26215..c14cba4990a738 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPUATTRS_TD
 
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
+include "mlir/IR/AttrTypeBase.td"
 include "mlir/IR/EnumAttr.td"
 
 class XeGPUAttr traits = [],
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
index c2f09319c790e0..765f218f95d269 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
@@ -17,12 +17,14 @@ def XeGPU_Dialect : Dialect {
 let summary = "The XeGPU dialect that models Intel GPU's ISA";
 let description = [{
   The XeGPU dialect models Intel Xe ISA semantics but works at vector and
-  TensorDesc data type. It provides 1:1 mappings to match Xe instructions 
+  TensorDesc data type. It provides 1:1 mappings to match Xe instructions
   like DPAS and 2D block load. The matrix size being processed at this 
level
   exactly matches the hardware instructions or the intrinsic supported by
   the lower-level GPU compiler.
 }];
 
+let dependentDialects = ["arith::ArithDialect"];
+
 let useDefaultTypePrinterParser = true;
 let useDefaultAttributePrinterParser = true;
 }
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
index a031a75984a536..3423609b76c706 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
@@ -9,7 +9,7 @@
 #ifndef MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 #define MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 
-include "mlir/IR/AttrTypeBase.td"
+include "mlir/Dialect/Arith/IR/ArithBase.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUAttrs.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUTypes.td"
@@ -35,7 +35,7 @@ class XeGPU_Op traits = []>:
 
 static ::mlir::ParseResult parseProperties(::mlir::OpAsmParser ,
  ::mlir::OperationState ) {
-  if (mlir::succeeded(parser.parseLess())) {
+  if (mlir::succeeded(parser.parseOptionalLess())) {
 

[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 updated 
https://github.com/llvm/llvm-project/pull/88439

>From 6021411059863c9a2bfdfc91e35628328e709a8c Mon Sep 17 00:00:00 2001
From: Chao Chen 
Date: Thu, 11 Apr 2024 15:46:26 -0500
Subject: [PATCH 1/2] Add dpas and named barrier ops

---
 .../mlir/Dialect/XeGPU/IR/CMakeLists.txt  |   6 +-
 mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h|   3 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUAttrs.td   |   1 +
 .../mlir/Dialect/XeGPU/IR/XeGPUDialect.td |   4 +-
 .../include/mlir/Dialect/XeGPU/IR/XeGPUOps.td | 154 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUTypes.td   |  11 ++
 mlir/lib/Dialect/XeGPU/IR/XeGPUOps.cpp|  23 +++
 mlir/test/Dialect/XeGPU/XeGPUOps.mlir |  57 ++-
 8 files changed, 250 insertions(+), 9 deletions(-)

diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt 
b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
index f1740e9ed929a6..3f8cac4dc07c3c 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
@@ -2,12 +2,12 @@ add_mlir_dialect(XeGPU xegpu)
 add_mlir_doc(XeGPU XeGPU Dialects/ -gen-dialect-doc -dialect=xegpu)
 
 set(LLVM_TARGET_DEFINITIONS XeGPU.td)
-mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls)
-mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs)
+mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls -attrdefs-dialect=xegpu)
+mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs -attrdefs-dialect=xegpu)
 add_public_tablegen_target(MLIRXeGPUAttrsIncGen)
 add_dependencies(mlir-headers MLIRXeGPUAttrsIncGen)
 
-set(LLVM_TARGET_DEFINITIONS XeGPU.td)
+set(LLVM_TARGET_DEFINITIONS XeGPUAttrs.td)
 mlir_tablegen(XeGPUEnums.h.inc -gen-enum-decls)
 mlir_tablegen(XeGPUEnums.cpp.inc -gen-enum-defs)
 add_public_tablegen_target(MLIRXeGPUEnumsIncGen)
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
index eca9255ff3974b..7ac0cf77fe59bb 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPU_H
 
 #include "mlir/Bytecode/BytecodeOpInterface.h"
+#include "mlir/Dialect/Arith/IR/Arith.h"
 #include "mlir/IR/BuiltinTypes.h"
 #include "mlir/IR/Dialect.h"
 #include "mlir/IR/TypeUtilities.h"
@@ -19,7 +20,7 @@
 
 namespace mlir {
 namespace xegpu {
-// placeholder
+class TensorDescType;
 } // namespace xegpu
 } // namespace mlir
 
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
index 6579d07ec26215..c14cba4990a738 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPUATTRS_TD
 
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
+include "mlir/IR/AttrTypeBase.td"
 include "mlir/IR/EnumAttr.td"
 
 class XeGPUAttr traits = [],
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
index c2f09319c790e0..765f218f95d269 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
@@ -17,12 +17,14 @@ def XeGPU_Dialect : Dialect {
 let summary = "The XeGPU dialect that models Intel GPU's ISA";
 let description = [{
   The XeGPU dialect models Intel Xe ISA semantics but works at vector and
-  TensorDesc data type. It provides 1:1 mappings to match Xe instructions 
+  TensorDesc data type. It provides 1:1 mappings to match Xe instructions
   like DPAS and 2D block load. The matrix size being processed at this 
level
   exactly matches the hardware instructions or the intrinsic supported by
   the lower-level GPU compiler.
 }];
 
+let dependentDialects = ["arith::ArithDialect"];
+
 let useDefaultTypePrinterParser = true;
 let useDefaultAttributePrinterParser = true;
 }
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
index a031a75984a536..3423609b76c706 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
@@ -9,7 +9,7 @@
 #ifndef MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 #define MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 
-include "mlir/IR/AttrTypeBase.td"
+include "mlir/Dialect/Arith/IR/ArithBase.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUAttrs.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUTypes.td"
@@ -35,7 +35,7 @@ class XeGPU_Op traits = []>:
 
 static ::mlir::ParseResult parseProperties(::mlir::OpAsmParser ,
  ::mlir::OperationState ) {
-  if (mlir::succeeded(parser.parseLess())) {
+  if (mlir::succeeded(parser.parseOptionalLess())) {
 

[llvm-branch-commits] [mlir] [MLIR][XeGPU] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 edited 
https://github.com/llvm/llvm-project/pull/88439
___
llvm-branch-commits mailing list
llvm-branch-commits@lists.llvm.org
https://lists.llvm.org/cgi-bin/mailman/listinfo/llvm-branch-commits

[llvm-branch-commits] [mlir] Add dpas and named barrier ops (PR #88439)

[Chao Chen via llvm-branch-commits]

https://github.com/chencha3 created 
https://github.com/llvm/llvm-project/pull/88439

This PR adds definition of dpas op, atomic op, named barrier and related ops. 

>From 6021411059863c9a2bfdfc91e35628328e709a8c Mon Sep 17 00:00:00 2001
From: Chao Chen 
Date: Thu, 11 Apr 2024 15:46:26 -0500
Subject: [PATCH] Add dpas and named barrier ops

---
 .../mlir/Dialect/XeGPU/IR/CMakeLists.txt  |   6 +-
 mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h|   3 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUAttrs.td   |   1 +
 .../mlir/Dialect/XeGPU/IR/XeGPUDialect.td |   4 +-
 .../include/mlir/Dialect/XeGPU/IR/XeGPUOps.td | 154 +-
 .../mlir/Dialect/XeGPU/IR/XeGPUTypes.td   |  11 ++
 mlir/lib/Dialect/XeGPU/IR/XeGPUOps.cpp|  23 +++
 mlir/test/Dialect/XeGPU/XeGPUOps.mlir |  57 ++-
 8 files changed, 250 insertions(+), 9 deletions(-)

diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt 
b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
index f1740e9ed929a6..3f8cac4dc07c3c 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/CMakeLists.txt
@@ -2,12 +2,12 @@ add_mlir_dialect(XeGPU xegpu)
 add_mlir_doc(XeGPU XeGPU Dialects/ -gen-dialect-doc -dialect=xegpu)
 
 set(LLVM_TARGET_DEFINITIONS XeGPU.td)
-mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls)
-mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs)
+mlir_tablegen(XeGPUAttrs.h.inc -gen-attrdef-decls -attrdefs-dialect=xegpu)
+mlir_tablegen(XeGPUAttrs.cpp.inc -gen-attrdef-defs -attrdefs-dialect=xegpu)
 add_public_tablegen_target(MLIRXeGPUAttrsIncGen)
 add_dependencies(mlir-headers MLIRXeGPUAttrsIncGen)
 
-set(LLVM_TARGET_DEFINITIONS XeGPU.td)
+set(LLVM_TARGET_DEFINITIONS XeGPUAttrs.td)
 mlir_tablegen(XeGPUEnums.h.inc -gen-enum-decls)
 mlir_tablegen(XeGPUEnums.cpp.inc -gen-enum-defs)
 add_public_tablegen_target(MLIRXeGPUEnumsIncGen)
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
index eca9255ff3974b..7ac0cf77fe59bb 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPU.h
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPU_H
 
 #include "mlir/Bytecode/BytecodeOpInterface.h"
+#include "mlir/Dialect/Arith/IR/Arith.h"
 #include "mlir/IR/BuiltinTypes.h"
 #include "mlir/IR/Dialect.h"
 #include "mlir/IR/TypeUtilities.h"
@@ -19,7 +20,7 @@
 
 namespace mlir {
 namespace xegpu {
-// placeholder
+class TensorDescType;
 } // namespace xegpu
 } // namespace mlir
 
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
index 6579d07ec26215..c14cba4990a738 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUAttrs.td
@@ -10,6 +10,7 @@
 #define MLIR_DIALECT_XEGPU_IR_XEGPUATTRS_TD
 
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
+include "mlir/IR/AttrTypeBase.td"
 include "mlir/IR/EnumAttr.td"
 
 class XeGPUAttr traits = [],
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
index c2f09319c790e0..765f218f95d269 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUDialect.td
@@ -17,12 +17,14 @@ def XeGPU_Dialect : Dialect {
 let summary = "The XeGPU dialect that models Intel GPU's ISA";
 let description = [{
   The XeGPU dialect models Intel Xe ISA semantics but works at vector and
-  TensorDesc data type. It provides 1:1 mappings to match Xe instructions 
+  TensorDesc data type. It provides 1:1 mappings to match Xe instructions
   like DPAS and 2D block load. The matrix size being processed at this 
level
   exactly matches the hardware instructions or the intrinsic supported by
   the lower-level GPU compiler.
 }];
 
+let dependentDialects = ["arith::ArithDialect"];
+
 let useDefaultTypePrinterParser = true;
 let useDefaultAttributePrinterParser = true;
 }
diff --git a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td 
b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
index a031a75984a536..3423609b76c706 100644
--- a/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
+++ b/mlir/include/mlir/Dialect/XeGPU/IR/XeGPUOps.td
@@ -9,7 +9,7 @@
 #ifndef MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 #define MLIR_DIALECT_XEGPU_IR_XEGPUOPS_TD
 
-include "mlir/IR/AttrTypeBase.td"
+include "mlir/Dialect/Arith/IR/ArithBase.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUAttrs.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUDialect.td"
 include "mlir/Dialect/XeGPU/IR/XeGPUTypes.td"
@@ -35,7 +35,7 @@ class XeGPU_Op traits = []>:
 
 static ::mlir::ParseResult parseProperties(::mlir::OpAsmParser ,
  ::mlir::OperationState ) {
-  if (mlir::succeeded(parser

[PyMOL] Question about formatting font size

[Chao Chen]

Dear Users,

I found in pymol layout somehow characters including protein sequence
letters become very small. Not sure what I have done. Any ideas of changing
to a bigger font? Thanks a lot in advance!

Kind regards,
Chao
___
PyMOL-users mailing list
Archives: http://www.mail-archive.com/pymol-users@lists.sourceforge.net
Unsubscribe: 
https://sourceforge.net/projects/pymol/lists/pymol-users/unsubscribe

Re: Error: Emacs File-local-variables error: (void-function beancount-mode)

[Chao Chen]

>
> (add-to-list 'load-path "/home/anthony/.emacs.d/lisp/")


I guess `beancount.el` is the folder `beancount-mode`? If so you're
supposed to put the folder in load-path, e.g., ` (add-to-list 'load-path
"/home/anthony/.emacs.d/lisp/*beancount-mode*")`.

If `beancount.el` is already in your emacs load-path, you can just try "M-x
load-file" to see whether it works.


Regards,
Chao

-- 
You received this message because you are subscribed to the Google Groups 
"Beancount" group.
To unsubscribe from this group and stop receiving emails from it, send an email 
to beancount+unsubscr...@googlegroups.com.
To view this discussion on the web visit 
https://groups.google.com/d/msgid/beancount/CAF6JJ%2BDqqJ54GEs%3Dun%2BT5RqWvzmXOr7o36XFdANc7MHZd7Sw-w%40mail.gmail.com.

Re: Error: Emacs File-local-variables error: (void-function beancount-mode)

[Chao Chen]

Have you put beancount.el in your emacs load-path? Make sure you can call beancount-mode from emacs.Regards,ChaoOn Oct 7, 2022, at 08:26, sadsada AJKnsjk  wrote:HelloI have been using beancount for sometime.  It works fine.I recently switched operating systems to OpenSuse.Current Emacs - GNU Emacs 28.1 (build 1, x86_64-suse-linux-gnu, GTK+ Version 3.24.34, cairo version 1.16.0)Issues:EMACS - Beancount Mode does not workFile-local-variables error: (void-function beancount-mode)Location of beancount.el~.emacs.d/lispalso created init.elPlease help if you can, I am not sure what is wrong. Also trying to use VIM, which I have never used.  If I can get either to work would be great.Thank You



-- 
You received this message because you are subscribed to the Google Groups "Beancount" group.
To unsubscribe from this group and stop receiving emails from it, send an email to beancount+unsubscr...@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/beancount/cfdb071c-c223-4cd8-b58e-88bd2f51a911n%40googlegroups.com.




-- 
You received this message because you are subscribed to the Google Groups "Beancount" group.
To unsubscribe from this group and stop receiving emails from it, send an email to beancount+unsubscr...@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/beancount/5115CAFE-7542-4D69-B5FB-5B7ABC9518CC%40gmail.com.

[NMusers] Clinical Pharmacology Modelling & Simulation Role at GlaxoSmithKline

[Chao Chen]

A new position has come up in our Clinical Pharmacology Modelling and 
Simulation Group (CPMS) at our Greater London site. This is an excellent role 
to use quantitative clinical pharmacology to accelerate the delivery of new 
medicines to patients, by enhancing drug development efficiency and business 
decision quality. The work directly supports our mission to help our patients 
do more, feel better and live longer.
The clinical PK/PD modeler will provide technical, therapeutic, and product 
development support for GlaxoSmithKline projects across all therapeutic areas. 
Individuals will ensure the optimal application of Clinical Pharmacokinetic 
(PK), Pharmacodynamic (PD), and Modelling & Simulation (MS) principles towards 
efficient drug development, risk management, and product registration. 
Responsibilities generally commence at pre-clinical candidate selection and 
continue through product lifecycle management.
Principle accountabilities include both modelling/simulation activities and 
clinical pharmacology support:
*   Plan, execute and report translational drug-disease modelling, 
exposure-response analysis, simulation-based trial design and population 
clinical pharmacology
*   Contribute to clinical program design, trial protocols, analysis plans, 
study reports and regulatory submissions
*   Apply innovative methods such as longitudinal exposure-response 
analysis, model-based meta-analysis and item-response analysis to improve data 
use and trial efficiency
*   Present strategy and defend outcome of model-based approaches to 
internal governance boards and regulatory agencies
*   Promote model-informed drug discovery and development through external 
collaboration, journal publication and conference presentation

Basic Qualifications/Competencies:
*   A doctorate relevant to Quantitative Clinical Pharmacology, and 
experience in using modelling/simulation to solve practical problems in 
industry or academia
*   Proven skills in PK/PD and longitudinal disease modelling; and 
verifiable proficiency in pharmacometric tools NONMEM, Monolix, R or SAS
*   Strong drive and learning agility to build knowledge on a drug-disease 
system, symptom progression, standard of care, and trial design and endpoints
*   Demonstrated aptitude for productive collaboration in a 
multi-discipline team, with effective communication and taking personal 
accountability for timely delivery of results
*   Clear evidence of ability to make sound judgement in complex situations 
and adapt to changing business needs by prioritising multiple tasks

Preferred Qualifications:
*   Experience in the design, analysis, interpretation and reporting of 
Clinical PK and PK/PD studies.
*   Experience or demonstrated aptitude in the application of clinical PK 
and PK/PD to the drug development process.
*   Knowledge of pharmacology, biology, drug metabolism, biopharmaceutics, 
regulatory affairs, therapeutics and commercialization such that he/she can 
assist in managing these interfaces and ensure that CPMS input meets their 
needs.

Why GSK?
Our values and expectations are at the heart of everything we do and form an 
important part of our culture. These include Patient focus, Transparency, 
Respect, Integrity along with Courage, Accountability, Development, and 
Teamwork. As GSK focuses on our values and expectations and a culture of 
innovation, performance, and trust, the successful candidate will demonstrate 
the following capabilities:

*   Operating at pace and agile decision-making - using evidence and 
applying judgement to balance pace, rigour and risk.
*   Committed to delivering high quality results, overcoming challenges, 
focusing on what matters, execution.
*   Continuously looking for opportunities to learn, build skills and share 
learning.
*   Sustaining energy and well-being
*   Building strong relationships and collaboration, honest and open 
conversations.
*   Budgeting and cost-consciousness

At GSK, we develop therapies of various modalities for a broad range of 
indications. As a member of a global department with diverse expertise, you 
will enjoy a highly supportive environment for scientific innovation, business 
impact and professional growth. Interested persons are encouraged to apply 
online 
here<https://jobs.gsk.com/en-gb/jobs/230574?lang=en-us=en-GB>.
Chao Chen
Clinical Pharmacology Modelling & Simulation
GlaxoSmithKline R

GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



  

This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), whi

[NMusers] Recall: Clinical Pharmacology Modelling & Simulation Role at GlaxoSmithKline

[Chao Chen]

Chao Chen would like to recall the message, "Clinical Pharmacology Modelling & 
Simulation Role at GlaxoSmithKline".
GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

[NMusers] Clinical Pharmacology Modelling & Simulation Role at GlaxoSmithKline

[Chao Chen]

A new position has come up in our Clinical Pharmacology Modelling and 
Simulation Group (CPMS) at our Greater London site. This is an excellent role 
to use quantitative clinical pharmacology to accelerate the delivery of new 
medicines to patients, by enhancing drug development efficiency and business 
decision quality. The work directly supports our mission to help our patients 
do more, feel better and live longer.
The clinical PK/PD modeler will provide technical, therapeutic, and product 
development support for GlaxoSmithKline projects across all therapeutic areas. 
Individuals will ensure the optimal application of Clinical Pharmacokinetic 
(PK), Pharmacodynamic (PD), and Modelling & Simulation (MS) principles towards 
efficient drug development, risk management, and product registration. 
Responsibilities generally commence at pre-clinical candidate selection and 
continue through product lifecycle management.
Principle accountabilities include both modelling/simulation activities and 
clinical pharmacology support:
*   Plan, execute and report translational drug-disease modelling, 
exposure-response analysis, simulation-based trial design and population 
clinical pharmacology
*   Contribute to clinical program design, trial protocols, analysis plans, 
study reports and regulatory submissions
*   Apply innovative methods such as longitudinal exposure-response 
analysis, model-based meta-analysis and item-response analysis to improve data 
use and trial efficiency
*   Present strategy and defend outcome of model-based approaches to 
internal governance boards and regulatory agencies
*   Promote model-informed drug discovery and development through external 
collaboration, journal publication and conference presentation

Basic Qualifications/Competencies:
*   A doctorate relevant to Quantitative Clinical Pharmacology, and 
experience in using modelling/simulation to solve practical problems in 
industry or academia
*   Proven skills in PK/PD and longitudinal disease modelling; and 
verifiable proficiency in pharmacometric tools NONMEM, Monolix, R or SAS
*   Strong drive and learning agility to build knowledge on a drug-disease 
system, symptom progression, standard of care, and trial design and endpoints
*   Demonstrated aptitude for productive collaboration in a 
multi-discipline team, with effective communication and taking personal 
accountability for timely delivery of results
*   Clear evidence of ability to make sound judgement in complex situations 
and adapt to changing business needs by prioritising multiple tasks

Preferred Qualifications:
*   Experience in the design, analysis, interpretation and reporting of 
Clinical PK and PK/PD studies.
*   Experience or demonstrated aptitude in the application of clinical PK 
and PK/PD to the drug development process.
*   Knowledge of pharmacology, biology, drug metabolism, biopharmaceutics, 
regulatory affairs, therapeutics and commercialization such that he/she can 
assist in managing these interfaces and ensure that CPMS input meets their 
needs.

Why GSK?
Our values and expectations are at the heart of everything we do and form an 
important part of our culture. These include Patient focus, Transparency, 
Respect, Integrity along with Courage, Accountability, Development, and 
Teamwork. As GSK focuses on our values and expectations and a culture of 
innovation, performance, and trust, the successful candidate will demonstrate 
the following capabilities:

*   Operating at pace and agile decision-making - using evidence and 
applying judgement to balance pace, rigour and risk.
*   Committed to delivering high quality results, overcoming challenges, 
focusing on what matters, execution.
*   Continuously looking for opportunities to learn, build skills and share 
learning.
*   Sustaining energy and well-being
*   Building strong relationships and collaboration, honest and open 
conversations.
*   Budgeting and cost-consciousness

At GSK, we develop therapies of various modalities for a broad range of 
indications. As a member of a global department with diverse expertise, you 
will enjoy a highly supportive environment for scientific innovation, business 
impact and professional growth. This position is open for application till 
Wednesday 5th August 2019. Interested persons are encouraged to apply online 
here<https://jobs.gsk.com/en-gb/jobs/230574?lang=en-us=en-GB>.
Chao Chen
Clinical Pharmacology Modelling & Simulation
GlaxoSmithKline R

GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



  

This e-mail was sent by GlaxoSmithKline Services Unlimit

[NMusers] Quantitative Clinical Pharmacology Position at GSK

[Chao Chen]

We have an exciting opportunity at GlaxoSmithKline (GSK) for a highly motivated 
Quantitative Clinical Pharmacologist to join our London team as part of the 
global department of Clinical Pharmacology Modelling & Simulation. This is an 
excellent role to use quantitative clinical pharmacology to accelerate the 
delivery of new medicines to patients by enhancing drug program efficiency and 
business decision quality. The work directly supports our mission to help our 
patients do more, feel better and live longer.
Responsibilities will include:
1. Plan, execute and report translational drug-disease modelling, 
exposure-response analysis, simulation-based trial design and population 
clinical pharmacology
*   2. Contribute to clinical program design, trial protocols, analysis 
plans, study reports and regulatory submissions
*   3. Apply innovative techniques such as longitudinal exposure-response 
analysis, model-based meta-analysis and item-response analysis to improve data 
use and trial efficiency
*   4. Present strategy and discuss outcome of model-based approaches via 
interactions with internal governance boards and regulatory agencies
*   5. Promote model-informed drug discovery and development through 
external collaboration, journal publication and conference presentation
Qualification requirements:
1. A doctorate relevant to Quantitative Clinical Pharmacology, and experience 
in using modelling/simulation to solve practical problems in industry or 
academia
2. Proven skills in pharmacokinetic-pharmacodynamic and longitudinal disease 
modelling; and verifiable proficiency in pharmacometric tools NONMEM, Monolix, 
R or SAS
3. Strong drive and learning agility to build knowledge on a drug-disease 
system, symptom progression, standard of care, and trial design and endpoints
4. Demonstrated aptitude for productive collaboration in a multi-discipline 
team, using effective communication and taking personal accountability for 
timely delivery of results
5. Clear evidence of ability to make sound judgement in complex situations and 
adapt to changing business needs by prioritising multiple tasks
The job level will depend on the skills and achievements of the successful 
candidate. At GSK, we develop therapies of various modalities for a broad range 
of indications. As a member of a global department with diverse expertise, you 
will enjoy a highly supportive environment for scientific innovation, business 
impact and professional growth. This position is open for application till 
Wednesday 5th August 2019. Interested persons are encouraged to apply online 
here<https://careers.peopleclick.com/careerscp/client_gsk/external1931/gateway.do?functionName=viewFromLink=410854=en-us>.
Chao Chen
Clinical Pharmacology Modelling & Simulation
GlaxoSmithKline R


GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

[NMusers] Quantitative Clinical Pharmacology Position at GSK

[Chao Chen]

We have an exciting opportunity at GlaxoSmithKline (GSK) for a highly motivated 
Quantitative Clinical Pharmacologist to join our London team as part of the 
global department of Clinical Pharmacology Modelling & Simulation. This is an 
excellent role to use quantitative clinical pharmacology to accelerate the 
delivery of new medicines to patients by enhancing drug program efficiency and 
business decision quality. The work directly supports our mission to help our 
patients do more, feel better and live longer. The job level will depend on the 
skills and achievements of the successful candidate.

Responsibilities will include:

*   Plan, execute and report translational drug-disease modelling, 
exposure-response analysis, simulation-based trial design and population 
clinical pharmacology
*   Contribute to clinical program design, trial protocols, analysis plans, 
study reports and regulatory submissions
*   Apply innovative techniques such as longitudinal exposure-response 
analysis, model-based meta-analysis and item-response analysis to improve data 
use and trial efficiency
*   Present strategy and discuss outcome of model-based approaches via 
interactions with governance boards and regulatory agencies
*   Promote model-informed drug discovery and development through external 
collaboration, journal publication and conference presentation

Qualification requirements:

*   A doctorate relevant to Quantitative Clinical Pharmacology, and 
experience in using modelling/simulation to solve practical problems in 
industry or academia
*   Proven skills in pharmacokinetic-pharmacodynamic and longitudinal 
disease modelling; and verifiable proficiency in pharmacometric tools NONMEM, 
Monolix, R or SAS
*   Strong drive and learning agility to build knowledge on a drug-disease 
system, symptom progression, standard of care, and trial design and endpoints
*   Demonstrated aptitude for productive collaboration in a 
multi-discipline team, using effective communication and taking personal 
accountability for timely delivery of results
*   Clear evidence of ability to make sound judgement in complex situations 
and adapt to changing business needs by prioritising multiple tasks

At GSK, we develop therapies of various modalities for a broad range of 
indications. As a member of a global department with diverse expertise, you 
will enjoy a highly supportive environment for scientific innovation, business 
impact and professional growth. This position is open for application till 
Wednesday 19th June 2019. Interested persons are encouraged to apply online 
here<https://careers.peopleclick.com/careerscp/client_gsk/external1931/gateway.do?functionName=viewFromLink=410854=en-us>.

Chao Chen
Clinical Pharmacology Modelling & Simulation
GlaxoSmithKline R


GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



  

This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

[NMusers] Quantitative Clinical Pharmacology Position at GSK

[Chao Chen]

GlaxoSmithKline (GSK) has an exciting position for a highly motivated 
Quantitative Clinical Pharmacologist to join our London team as a member of the 
global department of Clinical Pharmacology Modelling & Simulation. The job 
level will depend on the skills and achievements of the successful candidate. 
This is an excellent opportunity to use quantitative clinical pharmacology to 
accelerate the delivery of new medicines to patients by enhancing drug program 
efficiency and business decision quality.
Responsibilities:
*   Plan, execute and report translational drug-disease modelling, 
exposure-response analysis, simulation-based trial design and population 
clinical pharmacology
*   Contribute to asset clinical development and registration in terms of 
program plans, trial protocols, analysis plans, study reports and regulatory 
submissions
*   Assess and apply innovative techniques such as longitudinal 
exposure-response analysis, model-based meta-analysis and item-response 
analysis to maximise data use, trial efficiency and analytical power
*   Present strategy and discuss outcome of model-based approaches during 
interactions with internal governance boards and regulators
*   Promote model-informed drug discovery and development through external 
collaboration, journal publication and conference presentation

Requirements:
*   A doctorate in a field relevant to quantitative clinical pharmacology, 
and experience in using modelling/simulation to solve practical problems in 
industry or academia
*   Proven skills in pharmacokinetic-pharmacodynamic and longitudinal 
disease modelling; and verifiable proficiency in pharmacometric tools NONMEM, 
Monolix, R or SAS
*   Strong drive and learning agility to quickly build knowledge on a 
drug-disease system, symptom progression, trial design/endpoints and current 
treatments
*   Demonstrated aptitude for productive collaboration in a 
multi-discipline team, using effective communication and taking personal 
accountability for timely delivery of results
*   Clear evidence of ability to make sound judgement in complex situations 
and adapt to changing business needs by prioritising multiple tasks

At GSK, we develop therapies of various modalities for a broad range of 
indications. As a member of a global department with diverse expertise, you 
will enjoy a highly supportive environment for scientific innovation, business 
impact and professional growth. Interested persons are encouraged to apply 
online 
here<https://careers.peopleclick.com/careerscp/client_gsk/external1931/gateway.do?functionName=viewFromLink=406201=en-us>.
Chao Chen
Clinical Pharmacology Modelling & Simulation
GlaxoSmithKline R

GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



  

This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

[go-nuts] Re: Proposal: Shared libraries in Go, take 2 (+linux/amd64 implementation)

[Chao Chen]

I don't understand initial exec TLS model. But I meet the following problem 
when use go shared library. *When I load Go shared library from python2.7 
script on alpine 3.9 container.**Would you please give some suggestions? I 
am so appreciated for your help!*
*When I call Go shared library from python2.7 script on alpine 3.9 
container.*failed with OSError: Error relocating ./cc.so: : initial-exec 
TLS resolves to dynamic definition in ./cc.so 



/usr/src/app # go build -o cc.so -buildmode=c-shared main.go


/usr/src/app # readelf -d cc.so


Dynamic section at offset 0x10cd10 contains 22 entries:

Tag Type Name/Value

0x0001 (NEEDED) Shared library: [libc.musl-x86_64.so.1]

0x0010 (SYMBOLIC) 0x0

0x000c (INIT) 0x42000

0x000d (FINI) 0x92ed9

0x0019 (INIT_ARRAY) 0xa2078

0x001b (INIT_ARRAYSZ) 8 (bytes)

0x6ef5 (GNU_HASH) 0x270

0x0005 (STRTAB) 0xa50

0x0006 (SYMTAB) 0x378

0x000a (STRSZ) 1026 (bytes)

0x000b (SYMENT) 24 (bytes)

0x0003 (PLTGOT) 0x10deb0

0x0002 (PLTRELSZ) 720 (bytes)

0x0014 (PLTREL) RELA

0x0017 (JMPREL) 0x41a00

0x0007 (RELA) 0xe58

0x0008 (RELASZ) 265128 (bytes)

0x0009 (RELAENT) 24 (bytes)

0x001e (FLAGS) SYMBOLIC BIND_NOW STATIC_TLS

0x6ffb (FLAGS_1) Flags: NOW NODELETE

0x6ff9 (RELACOUNT) 11040

0x (NULL) 0x0


/usr/src/app # python test.py

Traceback (most recent call last):

File "test.py", line 2, in 

lib = ctypes.cdll.LoadLibrary('./cc.so')

File "/usr/lib/python2.7/ctypes/init.py", line 444, in LoadLibrary

return self._dlltype(name)

File "/usr/lib/python2.7/ctypes/init.py", line 366, in init

self._handle = _dlopen(self._name, mode)

OSError: Error relocating ./cc.so: : initial-exec TLS resolves to dynamic 
definition in ./cc.so
- show quoted text -
Code:
//main.go package main import "C" //export add func add(left, right int) 
int { return left + right } //export minus func minus(left, right int) int 
{ return left - right } //export multiply func multiply(left, right int) 
int { return left * right } //export divide func divide(left, right int) 
int { return left / right } //export testPrint func testPrint(){ 
print("test") } func main() { } // test.py import ctypes lib = 
ctypes.cdll.LoadLibrary('./cc.so') if lib is not None: print ("can load so")

On Thursday, May 30, 2013 at 4:16:35 AM UTC+8, Elias Naur wrote:
>
> Hi,
>
> A few months ago, I got some CLs reviewed and submied that added some low 
> level work towards support for creating shared libraries written in Go. The 
> more intrusive runtime changes were never accepted, so I'd like to propose 
> a more clean, simple, and hopefully more acceptable way of supporting 
> shared library in the Go runtime and tools. This proposal uses linux 
> terminology, but shared libraries on the other OSes are (hopefully) similar.
>
> *Go shared libraries*
> Supplying the -shared flag to 6l will output a shared library that is 
> similar to a go program, but with a few notable differences:
>
> Just as a go program includes all the referenced go code and the go 
> runtime, a go shared library is a dynamic shared object (.so file) that 
> includes all the referenced go code and the runtime.
>
> When a go program is executed, the main thread calls into the Go runtime, 
> which is initialized, init functions are run and finally, main() is run. A 
> go library does not own the native program's main thread, and in fact might 
> not even be loaded from the main thread (in the dlopen() case).
> Instead, the thread loading the go library spawns a new thread which from 
> then on functions as the Go main thread. The fresh go main thread in turn 
> runs go runtime initialization and then notifies the loading thread to 
> return control to the main program. The runtime initialization for go 
> libraries is the same as for ordinary go programs, except that main() is 
> expected to return, and that go won't exit the program when that happens.
> I don't have strong feelings about running main() or not, but running it 
> is the closest to normal go program behaviour, and then main() can double 
> as a "library init" function.
> After initialization, the main program can call into the Go library just 
> as if a foreign thread called into Go in a Cgo program.
>
> Deadlock detection is effectively disabled in go libraries, even if no cgo 
> calls have been made from Go, because it can't be known whether the main 
> program is deadlocked or not.
>
> os.Args normally contain the programs arguments. Shared libraries 
> generally don't have access to the program arguments without cooperation 
> from the main program, so os.Args length is 0 for go libraries.
>
> 

[go-nuts] Re: buildmode=c-archive and statically linking into another lib

[Chao Chen]

*Do you any progress to solve the problem? I meet the same problem.*

w 
hen
 
I call golang build shared library on python from alpine 3.9 container.failed 
with OSError: Error relocating ./cc.so: : initial-exec TLS resolves to 
dynamic definition in ./cc.so 


/usr/src/app # go build -o cc.so -buildmode=c-shared main.go


/usr/src/app # readelf -d cc.so


Dynamic section at offset 0x10cd10 contains 22 entries:

Tag Type Name/Value

0x0001 (NEEDED) Shared library: [libc.musl-x86_64.so.1]

0x0010 (SYMBOLIC) 0x0

0x000c (INIT) 0x42000

0x000d (FINI) 0x92ed9

0x0019 (INIT_ARRAY) 0xa2078

0x001b (INIT_ARRAYSZ) 8 (bytes)

0x6ef5 (GNU_HASH) 0x270

0x0005 (STRTAB) 0xa50

0x0006 (SYMTAB) 0x378

0x000a (STRSZ) 1026 (bytes)

0x000b (SYMENT) 24 (bytes)

0x0003 (PLTGOT) 0x10deb0

0x0002 (PLTRELSZ) 720 (bytes)

0x0014 (PLTREL) RELA

0x0017 (JMPREL) 0x41a00

0x0007 (RELA) 0xe58

0x0008 (RELASZ) 265128 (bytes)

0x0009 (RELAENT) 24 (bytes)

0x001e (FLAGS) SYMBOLIC BIND_NOW STATIC_TLS

0x6ffb (FLAGS_1) Flags: NOW NODELETE

0x6ff9 (RELACOUNT) 11040

0x (NULL) 0x0


/usr/src/app # python test.py

Traceback (most recent call last):

File "test.py", line 2, in 

lib = ctypes.cdll.LoadLibrary('./cc.so')

File "/usr/lib/python2.7/ctypes/init.py", line 444, in LoadLibrary

return self._dlltype(name)

File "/usr/lib/python2.7/ctypes/init.py", line 366, in init

self._handle = _dlopen(self._name, mode)

OSError: Error relocating ./cc.so: : initial-exec TLS resolves to dynamic 
definition in ./cc.so

On Wednesday, May 25, 2016 at 7:14:02 AM UTC+8, Justin Israel wrote:
>
> I've got one more question, related to this process, now that this library 
> is seeing some production use...
>
> The C++ Go binding shared library is being used as a dependency in another 
> library. This other library is a plugin that gets loaded via dlopen. I am 
> seeing the following:
>
> dlopen: cannot load any more object with static TLS
>
> In doing some research, I found that this happens when shared libs default 
> or use "-ftls-model=initial-exec" and/or don't use "-fpic". So it a 
> situation of the big pool of plugins that get dlopen'd into this particular 
> application, and the static TLS slots running out when enough of them use 
> initial-exec. 
>
> I was looking at my shared lib that is created via "go build 
> -buildmode=c-shared -gcflags=-shared -asmflags=-shared 
> -installsuffix=_shared -a" and I do see it using "-fPIC". After doing some 
> SO research, someone suggested doing the following to determine the TLS 
> mode that is being used:
>
>
> http://stackoverflow.com/questions/22983986/is-there-a-way-to-determine-thread-local-storage-model-used-by-a-library-on-linu
>
> $ readelf -d libgofileseq.so | grep FLAGS
> ... (FLAGS)SYMBOLIC STATIC_TLS
>
> It seems no combination of trying to add "-ftls-model=global-dynamic" to 
> my compile process can resolve the problem. Are there any suggestions of 
> where this change can be applied, to correct the situation where dlopen 
> fails? We have found that if this plugin using this shared library gets 
> loaded first, then we don't encounter the static TLS failure. 
>
> Justin
>
>
>
> On Wednesday, May 18, 2016 at 3:11:57 PM UTC+12, Justin Israel wrote:
>>
>> I'm wondering if someone can tell me if this is either a limitation of 
>> buildmode=c-archive static libs, or if I am really just doing something 
>> wrong.
>>
>> Problematic steps:
>>
>>1. export functions to  libgofoo.a using buildmode=c-archive
>>2. statically link libgofoo.a into another library to produce libfoo.a
>>3. Someone else consumes libfoo.a and libgofoo.a in their library, 
>>and get linker errors about:
>>ld: libgofoo.a(go.o): relocation R_X86_64_TPOFF32 against 
>>`runtime.tlsg` can not be used when making a shared object; recompile 
>> with 
>>-fPIC
>>libgofoo.a: could not read symbols: Bad value
>>
>> But library that wants to consume these libs can do so if they 
>> dynamically link with shared libs from c-shared. Also, if the consumer 
>> of the libs is a main binary, then the static linking works and does not 
>> complain. It is only when the target is a library.
>>
>> I could swear I went through and ensured -fPIC was being used, but it 
>> didn't seem to make a difference. Am I infact just messing up my 
>> compilation settings and failing to add this flag as it suggests, or is 
>> there a known limitation related to the steps I have outlined?
>>
>> Thanks!
>> Justin
>>
>>

-- 

[PyMOL] a question about slow response

[Chao Chen]

Hello PyMOL-users,

Previously I used older version of Pymol, and found it was very slow to
respond when I tried to click residues/chains in the software. I thought
updating the software would solve the problem. Now I have the latest
version of PyMOL 2.3.0 (Python 3.7.2 64-bit), unfortunately it still runs
slowly. Any suggestions are very welcome.

Kind regards,

Chao
___
PyMOL-users mailing list
Archives: http://www.mail-archive.com/pymol-users@lists.sourceforge.net
Unsubscribe: 
https://sourceforge.net/projects/pymol/lists/pymol-users/unsubscribe

[NMusers] Pharmacometrician Role at GSK

[Chao Chen]

GlaxoSmithKline (GSK) has a two-year position for a highly motivated 
Pharmacometrician to join our global department of Clinical Pharmacology 
Modelling & Simulation. This is an excellent opportunity to apply 
pharmacometrics to accelerating the delivery of new medicines to patients by 
enhancing drug program efficiency and business decision quality.
The main project will be applying Item Response Theory to rating scales in 
neurodegenerative diseases. Embedded in an organization where we develop 
therapies of various modalities for a broad range of indications at stages from 
pre-clinical to post-approval development, you will have tremendous 
opportunities for broad exposure to drug discovery and development.
Responsibilities:
*   Plan, conduct and report item response modelling, disease progression 
modelling, simulation-based trial design and exposure-response analysis to 
maximise data use, trial efficiency and analysis power
*   Contribute to clinical trial design, and discuss modelling strategy and 
outcome to project teams and governance boards
*   Promote model-informed drug discovery and development through 
internal/external collaboration, journal publication and conference presentation
Requirements:
*   Advanced training in pharmacometrics or statistics, and experience in 
using modelling/simulation to solve practical problems in industry or academia
*   Familiarity with item response theory, longitudinal disease modelling 
and model-based meta-analysis; proficiency with software NONMEM, MONOLIX, R and 
SAS
*   Aptitude for productive collaboration in a multi-discipline team, 
effective communication and taking personal accountability for timely result 
delivery
Working in a department of diverse expertise and on multi-discipline teams, you 
will enjoy a highly supportive environment for innovation, influence and 
growth. The ideal primary work location will be in London (UK) or Philadelphia 
(USA) area, though there is flexibility for the right candidate. Interested 
persons are encouraged to apply online 
here<https://careers.peopleclick.com/careerscp/client_gsk/external1931/gateway.do?functionName=viewFromLink=403072=en-us>.
Chao Chen
Clinical Pharmacology Modelling & Simulation, GSK R

GSK monitors email communications sent to and from GSK in order to protect GSK, 
our employees, customers, suppliers and business partners, from cyber threats 
and loss of GSK Information. GSK monitoring is conducted with appropriate 
confidentiality controls and in accordance with local laws and after 
appropriate consultation.



  

This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

[gem5-users] Instruction trace address for ARM architecture

[Chao Chen]

Hi all,

I used Gem5 to obtain instruction accesses for ARM processor. I used
-marm option to generate code.

arm-linux-gnueabihf-gcc -static -marm fibcall.c

I believe that only 32-bit ARM instructions are generated using this
option. But the result is shown below:

command line: ./build/ARM/gem5.opt --debug-flags=Exec
configs/example/se.py -c tests/test-progs/malardalen/a.out

Global frequency set at 1 ticks per second
 REAL SIMULATION 
info: Entering event queue @ 0.  Starting simulation...
  0: system.cpu T0 : @fini+15:   mov.w   fp, #0   :
IntAlu :  D=0x
500: system.cpu T0 : @_start+3:   mov.w   lr, #0   :
IntAlu :  D=0x
   1000: system.cpu T0 : @_start+7: ldmstm
   1000: system.cpu T0 : @_start+7.0  :   ldr_uop   r1, [sp, #0]   :
MemRead :  D=0x0001 A=0xbe00
   1500: system.cpu T0 : @_start+7.1  :   addi_uop   sp, sp, #4:
IntAlu :  D=0xbe04
   2000: system.cpu T0 : @_start+9:   mov   r2, sp :
IntAlu :  D=0xbe04
   2500: system.cpu T0 : @_start+11: ldmstm
   2500: system.cpu T0 : @_start+11.0  :   str_uop   r2, [sp, #4]   :
MemWrite :  D=0xbe04 A=0xbe00
   3000: system.cpu T0 : @_start+11.1  :   subi_uop   sp, sp, #4:
IntAlu :  D=0xbe00
   3500: system.cpu T0 : @_start+13: ldmstm
   3500: system.cpu T0 : @_start+13.0  :   str_uop   r0, [sp, #4]   :
MemWrite :  D=0x A=0xbefffefc
   4000: system.cpu T0 : @_start+13.1  :   subi_uop   sp, sp, #4:
IntAlu :  D=0xbefffefc
   4500: system.cpu T0 : @_start+15:   ldr.w   r12, [pc, #16]   :
MemRead :  D=0x9039 A=0x88d8
   5000: system.cpu T0 : @_start+19:   str.w   r12, [sp, #-4]!
   5000: system.cpu T0 : @_start+19.0  :   str.w   r12, [sp, #-4]!  :
MemWrite :  D=0x9039 A=0xbefffef8
   5500: system.cpu T0 : @_start+19.1  :   subi_uop.w   sp, sp, #4  :
IntAlu :  D=0xbefffef8
   6000: system.cpu T0 : @_start+23:   ldr   r0, [pc, #12]  :
MemRead :  D=0x8a4c A=0x88dc

...

We can see that at 2000, _start+9 is used, which is 2 bytes from _start+7.
So I think a 16-bit instruction is used. Why is it so? Why is it not 32-bit?

Besides, does anyone know what _start+7.0 and _start+7.1 mean? Why do I
have two different instructions with the same memory address?

Thanks in advance.

-- 
Chao Chen, PhD Student
MIST Lab - mistlab.ca
École Polytechnique de Montréal
___
gem5-users mailing list
gem5-users@gem5.org
http://m5sim.org/cgi-bin/mailman/listinfo/gem5-users

Spark Job always cause a node to reboot

[Chao Chen]

Hi all, 
I am new to spark. I am trying to deploy HDFS (hadoop-2.6.0) and Spark-1.3.1 
with four nodes, and each node has 8-cores and 8GB memory.
One is configured as headnode running masters, and 3 others are workers 

But when I try to run the Pagerank from HiBench, it always cause a node to 
reboot during the middle of the work for all scala, java, and python versions. 
But works fine
with the MapReduce version from the same benchmark. 

I also tried standalone deployment, got the same issue. 

My spark-defaults.conf
spark.masteryarn-client
spark.driver.memory 4g
spark.executor.memory   4g
spark.rdd.compress  false   


The job submit script is:

bin/spark-submit  --properties-file 
HiBench/report/pagerank/spark/scala/conf/sparkbench/spark.conf --class 
org.apache.spark.examples.SparkPageRank --master yarn-client --num-executors 2 
--executor-cores 4 --executor-memory 4G --driver-memory 4G 
HiBench/src/sparkbench/target/sparkbench-4.0-SNAPSHOT-MR2-spark1.3-jar-with-dependencies.jar
 hdfs://discfarm:9000/HiBench/Pagerank/Input/edges 
hdfs://discfarm:9000/HiBench/Pagerank/Output 3

What is problem with my configuration ? and How can I find the cause ?

any help is welcome !











-
To unsubscribe, e-mail: user-unsubscr...@spark.apache.org
For additional commands, e-mail: user-h...@spark.apache.org

[NMusers] Quantitative Clinical Pharmacology Positions at GlaxoSmithKline

[Chao Chen]

The department of Clinical Pharmacology Modelling and Simulation at 
GlaxoSmithKline is recruiting several quantitative clinical pharmacologists, at 
levels from Scientist to Senior Director. Successful candidates will have the 
opportunity to work on both small molecules and biologics in therapy areas 
including immunoinflammation, metabolic pathways, respiration, oncology, 
infection, neurosciences, dermatology, cardiovascular diseases and others. 
Positions are based in Stevenage and Uxbridge in the UK and in Upper Merion in 
the USA.
Responsibilities may include:

* Contribute, as a member of a multi-discipline team, to the design of 
an efficient clinical development program and a robust registration package

* Play a central role in predicting human dose range, characterising 
dose-response relationship and justifying dose recommendations for special 
populations

* Develop mathematical and statistical models to understand a disease, 
its progression, and pharmacodynamics and pharmacokinetics; conduct 
meta-analyses as appropriate to maximise data use; conduct simulations to 
assess trial design performance

* Design and interpret clinical pharmacology studies, including those 
to evaluate potential effects of intrinsic and extrinsic factors on 
pharmacokinetics and pharmacodynamics

* Write sections of drug development and registration documents such as 
clinical trial protocols and reports, clinical investigator brochures and 
regulatory submission packages

* Present and defend quantitative clinical pharmacology plans and 
results through interaction and negotiation with internal governance committees 
and external regulators

* Innovate through working effectively with colleagues in the 
department and others such as statisticians, biologists, physicians and drug 
metabolism scientists

* Learn and apply emerging modelling and simulation methodologies with 
a view to enhance clinical program efficiency and investment decision quality; 
collaborate with external field-leading teams for methodology application

* Promote model-informed drug development approach by publishing in 
peer-reviewed journals and presenting at scientific conferences
Basic and preferred qualifications are:

* Advanced training with a degree such as PhD, PharmD and MD to enable 
a successful career in quantitative clinical pharmacology in pharmaceutical 
research and development

* Knowledge of or ability to quickly learn the mechanism, endpoints, 
progression and treatments of relevant diseases

* Understanding of pharmacokinetic and pharmacodynamic principles and 
commonly applied models; working knowledge of common tools for quantitative 
clinical pharmacology such as NONMEM, R, WINNONLIN, Simcyp, SAS and MATLAB

* Experience in designing, analysing and reporting clinical studies, 
with a simulation- or modelling-based approach where appropriate

* Familiarity with regulatory submission documents such as CTAs, INDs, 
NDAs, MAAs and BLAs

* Ability to communicate clearly and succinctly with the audience in 
mind, both orally and in writing

* Ability to build effective collaboration while taking personal 
accountability for delivery of quantitative clinical pharmacology results

* Sound judgement, analytical mindset and problem-solving skills

* Ability to effectively multi-task and deliver results on time
GlaxoSmithKline provides a supportive environment for scientists who are 
aspired to learn, to contribute and to make impact on business decisions 
through innovation. We have several vacancies in our international department. 
The position level for a successful candidate will be based on the person's 
skills and experience. To apply, please visit our website 
(http://www.gsk.com/en-gb/careers/search-jobs-and-apply/) quoting req ID 
WD20837. Several members of our department will be attending this year's PAGE 
meeting 2nd - 6th June in Hersonissos, Greece. If you are also attending and 
would like to know more about these positions, please seek us out. We would be 
delighted to talk to you.
Chao Chen, PhD
Interim Global Head,
Clinical Pharmacology Modelling  Simulation
GlaxoSmithKline RD
chao.c.c...@gsk.commailto:chao.c.c...@gsk.com




This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

Contribute code

[Chao Chen]

Hi:

How do I contribute code to Matpower? Is there a github repository?

Chao Chen
Elmagin Capital

[NMusers] Quantitative Clinical Pharmacology Positions at GlaxoSmithKline

[Chao Chen]

The department of Clinical Pharmacology Modelling and Simulation at 
GlaxoSmithKline is recruiting several quantitative clinical pharmacologists, at 
levels from Scientist to Senior Director. Successful candidates will have the 
opportunity to work on both small molecules and biologics in therapy areas 
including immunoinflammation, metabolic pathways, respiration, oncology, 
infection, neurosciences, dermatology, cardiovascular diseases and others. 
Positions are based in Stevenage and Uxbridge in the UK and in Upper Merion in 
the USA.
Responsibilities may include:

* Contribute, as a member of a multi-discipline team, to the design of 
an efficient clinical development program and a robust registration package

* Play a central role in predicting human dose range, characterising 
dose-response relationship and justifying dose recommendations for special 
populations

* Develop mathematical and statistical models to understand a disease, 
its progression, and pharmacodynamics and pharmacokinetics; conduct 
meta-analyses as appropriate to maximise data use; conduct simulations to 
assess trial design performance

* Design and interpret clinical pharmacology studies, including those 
to evaluate potential effects of intrinsic and extrinsic factors on 
pharmacokinetics and pharmacodynamics

* Write sections of drug development and registration documents such as 
clinical trial protocols and reports, clinical investigator brochures and 
regulatory submission packages

* Present and defend quantitative clinical pharmacology plans and 
results through interaction and negotiation with internal governance committees 
and external regulators

* Innovate through working effectively with colleagues in the 
department and others such as statisticians, biologists, physicians and drug 
metabolism scientists

* Learn and apply emerging modelling and simulation methodologies with 
a view to enhance clinical program efficiency and investment decision quality; 
collaborate with external field-leading teams for methodology application

* Promote model-informed drug development approach by publishing in 
peer-reviewed journals and presenting at scientific conferences
Basic and preferred qualifications are:

* Advanced training with a degree such as PhD, PharmD and MD to enable 
a successful career in quantitative clinical pharmacology in pharmaceutical 
research and development

* Knowledge of or ability to quickly learn the mechanism, endpoints, 
progression and treatments of relevant diseases

* Understanding of pharmacokinetic and pharmacodynamic principles and 
commonly applied models; working knowledge of common tools for quantitative 
clinical pharmacology such as NONMEM, R, WINNONLIN, Simcyp, SAS and MATLAB

* Experience in designing, analysing and reporting clinical studies, 
with a simulation- or modelling-based approach where appropriate

* Familiarity with regulatory submission documents such as CTAs, INDs, 
NDAs, MAAs and BLAs

* Ability to communicate clearly and succinctly with the audience in 
mind, both orally and in writing

* Ability to build effective collaboration while taking personal 
accountability for delivery of quantitative clinical pharmacology results

* Sound judgement, analytical mindset and problem-solving skills

* Ability to effectively multi-task and deliver results on time
GlaxoSmithKline provides a supportive environment for scientists who are 
aspired to learn, to contribute and to make impact on business decisions 
through innovation. We have several vacancies. The position level for a 
successful candidate will be based on the person's skills and experience. To 
apply, please visit our website 
(http://www.gsk.com/en-gb/careers/search-jobs-and-apply/) quoting req ID 
WD20837.

Chao Chen, PhD
Interim Global Head,
Clinical Pharmacology Modelling  Simulation
GlaxoSmithKline RD
chao.c.c...@gsk.commailto:chao.c.c...@gsk.com





This e-mail was sent by GlaxoSmithKline Services Unlimited
(registered in England and Wales No. 1047315), which is a
member of the GlaxoSmithKline group of companies. The
registered address of GlaxoSmithKline Services Unlimited
is 980 Great West Road, Brentford, Middlesex TW8 9GS.

[Om-announce] Fwd: New UIC Submission Deadline (10th,April)

[Chao Chen]

-- Forwarded message --
From: Chao Chen ivanchao.c...@gmail.com
Date: Wed, Apr 1, 2015 at 2:38 PM
Subject: New UIC Submission Deadline (10th,April)
To:


Dear Authors,

Due to many requests from anthors, we decide to extend the submission
deadline of UIC conference.

The new deadline is *10th, April (Firm)*.

Pls submit your papers soon.

The information about* Special Issues *can be found in the link below.
http://www.cybermatics.org/SWC2015/Main_issue.htm

Below pls also find the CFP information.

*
Announcement and Call for Papers
**
UIC 2015
   http://www.cybermatics.org/SWC2015/UIC/UIC2015.htm

 The 12th IEEE International Conference on
   Ubiquitous Intelligence and Computing

August 10-14, 2015, Beijing, China

Ubiquitous sensors, devices, networks and information are paving the way
towards a smart world in which computational intelligence is distributed
throughout the physical environment to provide reliable and relevant
services to people. This ubiquitous intelligence will change the computing
landscape because it will enable new breeds of applications and systems to
be developed and the realm of computing possibilities will be significantly
extended. By enhancing everyday objects with intelligence, many tasks and
processes could be simplified, the physical spaces where people interact
like the workplaces and homes, could become more efficient, safer and more
enjoyable. Ubiquitous computing, or pervasive computing, uses these many
smart things or u-things to create smart environments, services and
applications.

Research on ubiquitous intelligence is an emerging research field covering
many disciplines. A series of grand challenges exist to move from the
current level of computing services to the smart world of adaptive and
intelligent services. Started in 2005, the series of Ubiquitous
Intelligence and Computing (UIC) conferences has been held in Taipei,
Nagasaki, Three Gorges (China), Hong Kong, Oslo, Brisbane, Xi'an, Banff,
Fukuoka, Vietri sul Mare (Italy) and Ayodya Resort (Bali, Indonesia). It
offers a forum for researchers to exchange ideas and experiences in
developing intelligent/smart objects, environments and systems.

The 12th IEEE International Conference on Ubiquitous Intelligence and
Computing (UIC 2015) will be held during August 10-14, 2015, in Beijing
China. It will include a highly selective program of technical papers,
accompanied by workshops, demos, panel discussions and keynote speeches. We
welcome high quality papers that describe original and unpublished research
advancing the state of the art in ubiquitous intelligence and computing.

Topics for submissions include but are not limited to the following :

Track1: Smart Objects and Interactions
- Electronic Labels, Cards, E-Tags and RFID
- Embedded Chips, Sensors, and Actuators
- MEMS, NEMS, Micro and Biometric Devices
- Smart Appliances
- Wearable Devices
- Material, Textile, Cloth, Furniture, etc.
- Embedded Software and Agents
- Interaction to Smart Objects and Devices
- Smart Object OS and Programming

Track 2: Smart Systems and Services
- Sensor, Ad Hoc, and P2P Networks
- Wearable, Personal and Body Area Systems
- Smart Systems Programming Models and Methodologies
- Intelligent Services and Architectures
- Agents Systems and Architectures
- Swarm Intelligence
- Context-aware Systems
- Big Data in Ubiquitous Systems
- Nature-inspired Intelligent Systems
- Knowledge Representation and Reasoning

Track 3: Smart Environments and Applications
- Urban Computing and Smart City
- Smart Home, Office, Laboratory, and Shop
- Intelligent Traffic and Transportation
- Intelligent Energy Consumption
- Intelligent Environmental Protection
- Smart Healthcare
- Smart Education
- Pervasive Games and Entertainment
- Smart Public Safety and Security

Track 4: Personalization and Social Aspects
- Social Computing
- Mobile Crowd Sensing
- Ubiquitous Computing for Computational Social Science
- Location-Based Social Networks
- Human Mobility Modeling and Mining
- Context-aware Computing
- Recommendation Systems for Ubiquitous Computing
- Human-centric Sensing
- Intelligent Socially-aware and Community-aware Systems
- Security, Privacy, Safety and Legal Issues

PAPER SUBMISSION
Main conference papers are limited to 8 pages, following the IEEE CS
format, and are to be submitted as PDF via the UIC 2015 submission site (
https://easychair.org/conferences/?conf=uic2015).

PAPER PUBLICATION
Accepted conference papers will be published by IEEE CPS (IEEE-DL and EI
indexed). At least one author of each accepted paper is required to
register and present their work at the conference; otherwise the paper will
not be included in the proceedings. Best Paper Awards will be presented to
high quality papers. Selected papers, after further extensions and
revisions, will be recommended to special issues

Re: Welcoming three new committers

[Chao Chen]

Congratulations guys, well done!

在 15-2-4 上午9:26, Nan Zhu 写道:

Congratulations!

--
Nan Zhu
http://codingcat.me


On Tuesday, February 3, 2015 at 8:08 PM, Xuefeng Wu wrote:


Congratulations！well done.
  
Yours, Xuefeng Wu 吴雪峰 敬上
  

On 2015年2月4日, at 上午6:34, Matei Zaharia matei.zaha...@gmail.com 
(mailto:matei.zaha...@gmail.com) wrote:
  
Hi all,
  
The PMC recently voted to add three new committers: Cheng Lian, Joseph Bradley and Sean Owen. All three have been major contributors to Spark in the past year: Cheng on Spark SQL, Joseph on MLlib, and Sean on ML and many pieces throughout Spark Core. Join me in welcoming them as committers!
  
Matei

-
To unsubscribe, e-mail: dev-unsubscr...@spark.apache.org 
(mailto:dev-unsubscr...@spark.apache.org)
For additional commands, e-mail: dev-h...@spark.apache.org 
(mailto:dev-h...@spark.apache.org)
  
  
  
-

To unsubscribe, e-mail: dev-unsubscr...@spark.apache.org 
(mailto:dev-unsubscr...@spark.apache.org)
For additional commands, e-mail: dev-h...@spark.apache.org 
(mailto:dev-h...@spark.apache.org)
  
  






-
To unsubscribe, e-mail: dev-unsubscr...@spark.apache.org
For additional commands, e-mail: dev-h...@spark.apache.org

[Pvfs2-users] FORTRAN I/O on Orangefs

[Chao Chen]

Hi all,

Recently, I am trying to run POP (Parallel Ocean Program, written with
fortran) with Orangefs. And found that there is always an I/O error
reporting parameter is not correct from POP if I configure it to output
file to Orangefs. But POP works fine if configure its output to NFS. I also
run IOR (written with C) with orangefs, and everything works fine too. Is
there anybody has experience of running fortran program on orangefs ? How
Can I figure out what's the problem?

I tested both kernel module client interface and fuse interface, with
orangefs-2.9.0 version.

Thanks


-- 

Best Regards !

Chao
___
Pvfs2-users mailing list
Pvfs2-users@beowulf-underground.org
http://www.beowulf-underground.org/mailman/listinfo/pvfs2-users

[gem5-users] Alpha ROB, IQ, LSQ overflow, or something related to cpu-instcount = 1500' failed

[Chao Chen]

Hi,

I am using the up-to-date gem5 version (repo.gem5.org/gem5). and run
the ALPHA arch with FS mode.
The system have many stalls due to lack of free ROB, IQ or LSQ,
although the simulation still procedes slowly.
I increase the ROB and IQ to 4048 entries each, but the stalls didn't
disappear. I increase the Load Queue to 4048 (I know it may be not
reasonable), but I cannot increase Store Queue to more than 128
entries, the simulation would halt.

I tried to debug with gem5.debug.
The simulation is aborted for void BaseDynInst
template-parameter-1-1 ::initVars() [with Impl = O3CPUImpl]:
Assertion `cpu-instcount = 1500' failed.
This was ignored when using gem5.fast earlier.

I see the other posts that it means the in flight instructions
increases beyond a reasonable limit

I have some questions I cannot understand.
1.  Is it reasonable that the in flight instructions increases while I
use large ROB and IQ size? I was expecting in-flight instructions
didn't increase and the stalled caused by lack of buffer would
disappear.
2. I tried to debug it myself, and find that some instructions are not
destroyed after committing. It seems they are never destroyed, and
kept somewhere in some queue (I don't know which queue).
For most (regular) instructions, when
instList.erase(removeList.front()) is called in o3/cpu.cc, the
instruction would be destroyed.
For some instructions, they are not destroyed properly after
calling instList.erase. I debug to find the reason is the reference
counter of the instruction object does not reach zero, and the system
would destroy the instruction object while nobody is still referencing
(using) this instruction. According to my understanding, there must be
somewhere in the pipeline that didn't decrease the reference
correctly, or some special operations (like squash) didn't call
functions to remove the reference.
3. I am not sure how this would cause the ROB and IQ to overflow (no
matter how big I set the values of these buffers).

Is there anyone see this kind of issues before? Is it really a bug or
did I do something wrong? If it is a bug, can you give me some hint to
detect which part may not have decrement the reference counter of the
instruction object? Any suspect?

Thanks,
Chao
___
gem5-users mailing list
gem5-users@gem5.org
http://m5sim.org/cgi-bin/mailman/listinfo/gem5-users

Re: Use STATIC_URL in templates

[Chao Chen]

hi ,in the Django files you can read the  docs/howto/static-files.txt

On Wed, Sep 12, 2012 at 10:12 PM, Axel Aguilar  wrote:

> Hello, I'm pretty new with django, exactly the same than with python, and
> after reading a few tutorials and make a very simple django site, I have a
> django/python question...
>
>
> I made this script in python:
>
> 
>
> import os
> import random
>
> url
> ='/home/usuario/django/projects/volei/volei/static/img/stories/fotos_jugadoras/'
>
> directorios = os.listdir(url)
>
> lista_ficheros = []
> for direc in directorios:
> url_ficheros = url+direc
> lista_ficheros.extend(os.listdir(url_ficheros))
>
> r = random.choice(lista_ficheros)
>
> 
>
> And it do exactly what I want, get a pic at random from a few folders.
>
> Ok, I have a few templates, and all of them inherit from base.html, and in
> base.html I want to add this random pics...
>
> I think the script goes in the view.py, but I don't know how it can be
> since no view goes directly (and at same time all indirectly) they end in
> base.html... I tried to put all the script in {% %} in the base.html, but
> it doen't work..
>
>
> I will explain briefly what I want to do only in case django or python
> have a easier way to do:
> get random image from a tree folder like this:
> folder/subfolder1/img.jpg
> folder/subfolder2/img2.jpg
> folder/subfolder3/img3.jpg
>
> I have an slide, and only showing one at once, so the idea was every time
> slide goes to show an image, it will get it from the random script...
>
> I don't know if I explain myself.. ^^'
>
> Thanks in advance!
>
> --
> You received this message because you are subscribed to the Google Groups
> "Django users" group.
> To view this discussion on the web visit
> https://groups.google.com/d/msg/django-users/-/T71GlSb01dwJ.
> To post to this group, send email to django-users@googlegroups.com.
> To unsubscribe from this group, send email to
> django-users+unsubscr...@googlegroups.com.
> For more options, visit this group at
> http://groups.google.com/group/django-users?hl=en.
>



-- 
幻想是一种生命！minixer

-- 
You received this message because you are subscribed to the Google Groups 
"Django users" group.
To post to this group, send email to django-users@googlegroups.com.
To unsubscribe from this group, send email to 
django-users+unsubscr...@googlegroups.com.
For more options, visit this group at 
http://groups.google.com/group/django-users?hl=en.

[gem5-users] Multi-Level Cache coherence

[Chao Chen]

Hi,

I find that in cache_impl.hh, when a cache receives a read request, it
would forward to upper level caches to check if they want to handle
it.
But I see the memInhibit flag is not forwarded. (not copied from
original packet to the forwarded packet)

In my simulation,
L2 of core 0 sends out a read request.
L2 of core 1 process it and set memInhibit flag.
L2 of core 2 forward the request to L1s of core2,  but the forwarded
request has memInhibit flag not set.
L1s of core2 respond the request again.

Such problem triggers the assert in cache_impl.hh.
Could any one help me how should I change to avoid the problem?

Thanks,
chao
___
gem5-users mailing list
gem5-users@gem5.org
http://m5sim.org/cgi-bin/mailman/listinfo/gem5-users

[gem5-users] Halt not implemented

[Chao Chen]

Hi,

We I run m5 in FS mode, I got the following error:

panic: Halt not implemented!
 @ cycle 2416905206000
[halt:build/ALPHA_FS/cpu/o3/cpu.hh, line 388]

Have anyone see such error before? Is there any solution for that?

Thanks,
Chao
___
gem5-users mailing list
gem5-users@gem5.org
http://m5sim.org/cgi-bin/mailman/listinfo/gem5-users

[Google Maps API v2] how can I access to the reviews on google map?

[Chao Chen]

Hi,

As a research graduate student, I am involved in a project that need to
access to the reviews of google map. For example, the cumtomer reviews of a
company in googleMap. So How can I access to this data? And is it free or
not? Do I need to apply a map key? Thanks!

Chao

-- 
You received this message because you are subscribed to the Google Groups 
Google Maps API V2 group.
To post to this group, send email to google-maps-api@googlegroups.com.
To unsubscribe from this group, send email to 
google-maps-api+unsubscr...@googlegroups.com.
For more options, visit this group at 
http://groups.google.com/group/google-maps-api?hl=en.

[m5-users] Packets with same dest and src

[Chao Chen]

Hi,

I find there are some broadcast packets in M5 interconnect. They have 
the same destinations are their source. I seems that in this case, the 
packets are deleted by source instead of memory or higher level cache. 
I could see a lot of this kinds of packets when simulating PARSEC 
benchmark but not any when running NAS benchmarks. Could anyone help 
explain what are these packets used for? Are they related with PARSEC 
hooks lib?


Thanks,
Chao

___
m5-users mailing list
m5-users@m5sim.org
http://m5sim.org/cgi-bin/mailman/listinfo/m5-users

[NMusers] Senior/Principle Modelling Simulation Position at GlaxoSmithKline (GSK)

[Chao Chen]

GlaxoSmithKline (GSK) has an opening for a Senior/Principle Scientist in the 
Clinical Pharmacology Modelling  Simulation Department in Harlow (UK) or 
Verona (Italy).

Driving the success of GlaxoSmithKline - one of the world's leading 
pharmaceutical organisations - is a continual search for innovation. In 
addition to the research and development capability that sets the benchmark for 
our industry, we're committed to recruiting and retaining the best and 
brightest by providing unequalled career development opportunities within the 
organisation.

Due to an increased commitment of GSK to the application of 
pharmacokinetics/pharmacodynamics (PK/PD), we now have an opportunity within 
our Clinical Pharmacology Modelling  Simulation Department. As a member of 
this department, you'll be part of a team exploring, learning and utilising 
state-of-the-art methodologies to enhance the understanding of PK/PD 
characteristics of compounds in the GSK portfolio. What's more, you'll be 
working across the GSK drug pipeline from pre-candidate selection through 
post-licensing within therapeutically-aligned groups.

By designing clinical PK and PD studies, participating in drug development 
teams, inputting into clinical development plans, conducting mathematical and 
statistical modelling of population PK/PD data and writing the critical 
components of regulatory documents, you will be the public face of Clinical 
Pharmacology Modelling  Simulation within and outside GSK.

With a PhD in Pharmacokinetics, Biopharmaceutics or a related field, an 
established track record in effectively applying clinical pharmacology 
principles and pharmacometric methodologies using NONMEM, S-PLUS, and/or other 
relevant tools, you'll have a sound understanding of clinical pharmacology and 
the role of PK and modelling in drug development. You need to have excellent 
written and verbal communication skills and be comfortable forming close and 
effective relationships with your colleagues throughout the business.

At GlaxoSmithKline we provide a supportive working environment, and a range of 
development challenges and opportunities. We also offer highly competitive 
benefits and compensation packages designed to attract and retain the very best 
talent.

If you are interested in this position please visit www.gsk.com/careers quoting 
Req ID 57392http://www.gsk.com/careers%20quoting%20Req%20ID%2057392.

Should you require more information about the position please contact Chao 
Chen: chao.c.c...@gsk.commailto:chao.c.c...@gsk.com.



---
This e-mail was sent by GlaxoSmithKline Services Unlimited 
(registered in England and Wales No. 1047315), which is a 
member of the GlaxoSmithKline group of companies. The 
registered address of GlaxoSmithKline Services Unlimited 
is 980 Great West Road, Brentford, Middlesex TW8 9GS.
---

[ns] Three-way handshake of TCP

[Chao Chen]

Who knows the three-way handshaking process is or not implemented in tcp.cc?
Or it is implemented in other files of tcp? 

 

Thanks,

Chao

 

Re: .\ in class path

[Chao Chen]

"." simply means the current working directory in MS-DOS.


In a message dated 7/28/00 11:01:42 PM Central Daylight Time,
[EMAIL PROTECTED] writes:

 Subj:   .\ in class path
  Date:7/28/00 11:01:42 PM Central Daylight Time
  From:[EMAIL PROTECTED] (B R Nair)
  Sender:  [EMAIL PROTECTED] (A mailing list about Java Server Pages
 specification and reference)
  Reply-to:[EMAIL PROTECTED] (A mailing list about Java Server
Pages
 specification and reference)
  To:  [EMAIL PROTECTED]

  Hello,

  In the
  SET CLASSPATH=C:\SBN\LEGAL.JAR;.\
  statement (MS DOS environment), what is the function of the last two
  characters, namely, ".\"?

  Thanx in advance.


===
To unsubscribe: mailto [EMAIL PROTECTED] with body: "signoff JSP-INTEREST".
Some relevant FAQs on JSP/Servlets can be found at:

 http://java.sun.com/products/jsp/faq.html
 http://www.esperanto.org.nz/jsp/jspfaq.html
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=JSP
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=Servlets

Re: Is it required to End the Custom Tag?

[Chao Chen]

In a message dated 7/24/00 5:43:58 AM Central Daylight Time,
[EMAIL PROTECTED] writes:

 Subj:   Is it required to End the Custom Tag?
  Date:7/24/00 5:43:58 AM Central Daylight Time
  From:[EMAIL PROTECTED] (Pratik)
  Sender:  [EMAIL PROTECTED] (A mailing list about Java Server Pages
 specification and reference)
  Reply-to:[EMAIL PROTECTED] (A mailing list about Java Server
Pages
 specification and reference)
  To:  [EMAIL PROTECTED]

  Hi Friends
  I would like to ask a silly but strange question.
  I start tag like qu:mytag and if I don't end that tag like /qu:mytag
  then also tomcat executes my tag
  It does not complain that tag should be ended properly

  Is this a tomcat Bug??
  I am using tomcat 3.1


No, this is not a bug.  The tag could be used in either of the following two
ways, depending on whether it is defined to be a container that makes use of
the tag library

qu:mytag
Arbitrary JSP
qu:mytag /

or just
qu:mytag /

  Please guide me

  Thanks in Advance


===
To unsubscribe: mailto [EMAIL PROTECTED] with body: "signoff JSP-INTEREST".
Some relevant FAQs on JSP/Servlets can be found at:

 http://java.sun.com/products/jsp/faq.html
 http://www.esperanto.org.nz/jsp/jspfaq.html
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=JSP
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=Servlets

Re: Servlet newbie question

[Chao Chen]

In a message dated 7/23/00 9:06:12 PM Central Daylight Time,
[EMAIL PROTECTED] writes:

 Subj:   Servlet newbie question
  Date:7/23/00 9:06:12 PM Central Daylight Time
  From:[EMAIL PROTECTED] (Amba Ayambem)
  Sender:  [EMAIL PROTECTED] (A mailing list for discussion
about
 Sun Microsystem's Java Servlet API Technology.)
  Reply-to:[EMAIL PROTECTED] (A mailing list for discussion
about
 Sun Microsystem's Java Servlet API Technology.)
  To:  [EMAIL PROTECTED]

  Greetings all. I am new to java servlets and have recently installed the
  jsdk2.1. I have also written the following HelloWorld.java servlet:

  ---
  import javax.servlet.GenericServlet;
  import javax.servlet.ServletException;
  import javax.servlet.ServletResponse;
  import javax.servlet.ServletRequest;
  import javax.servlet.ServletOutputStream;
  import java.io.IOException;

  public class HelloWorld extends javax.servlet.GenericServlet {
  public void service(ServletRequest req, ServletResponse res)
  throws ServletException, IOException {
  res.setContentType("text/html");
 servletOutputStream out = res.getOutputStream();

Java is case sensitive. Therefore you should use

   ServletOutputStream out = res.getOutputStream();


 out.println("Hello World");
  }
  }
  --

  The trouble is, when I try to compile it I get the following compiler
error:

  HelloWorld.java:12: cannot resolve symbol
  symbol : class  servletOutputStream
  location : class HelloWorld
  servletOutputStream out = res.getOutputStream();

  I have finally thrown in the towel on trying to figure out what in the
  world the "symbol" is that the compiler can't resolve. I need help!
  My CLASS contains C:\jsdk2.1 and
  my CLASSPATH contains C:\jsdk2.1\server.jar;.;C:\jsdk2.0\lib\jsdk.jar
  Thanks for any help.

  ---amba---



___
To unsubscribe, send email to [EMAIL PROTECTED] and include in the body
of the message "signoff SERVLET-INTEREST".

Archives: http://archives.java.sun.com/archives/servlet-interest.html
Resources: http://java.sun.com/products/servlet/external-resources.html
LISTSERV Help: http://www.lsoft.com/manuals/user/user.html

Tomcat failed to start

[Chao Chen]

Hi:

I have been using Tomcat on Windows 98 for sometime.  Recently, I was unable
to start Tomcat.  Looks like it failed during the execution of server
configuration file.  Can anyone tell me to way to detect the problem
associated with the port 8080 (default configuration for Tomcat)?  I
suspected that my Win98 is conflicting with Tomcat listening port.

Regards,
cfc

===
To unsubscribe: mailto [EMAIL PROTECTED] with body: "signoff JSP-INTEREST".
Some relevant FAQs on JSP/Servlets can be found at:

 http://java.sun.com/products/jsp/faq.html
 http://www.esperanto.org.nz/jsp/jspfaq.html
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=JSP
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=Servlets

Failed to start Tomcat

[Chao Chen]

Hi :

I have been using Tomcat on Windows 98 for sometime.  Recently, I was unable
to start Tomcat.  Looks like it failed during the execution of server
configuration file.  Can anyone tell me to way to detect the problem
associated with the port 8080 (default configuration for Tomcat)?  I
suspected that my Win98 is conflicting with Tomcat.

Thanks in advance.

cfc

___
To unsubscribe, send email to [EMAIL PROTECTED] and include in the body
of the message "signoff SERVLET-INTEREST".

Archives: http://archives.java.sun.com/archives/servlet-interest.html
Resources: http://java.sun.com/products/servlet/external-resources.html
LISTSERV Help: http://www.lsoft.com/manuals/user/user.html

IDE for JSP/Servlet

[Chao Chen]

Hello members!

Can anyone recommend a good IDE for Java application development, especially
in the area of JSP/Servlet ?  How good is JBuilder 3.5?  Dealing  with
compilation and run-time errors associated with JSPs has been quite
frustrating.  Your answers might help reduce the pain.  Thanks.

Cheers

===
To unsubscribe: mailto [EMAIL PROTECTED] with body: "signoff JSP-INTEREST".
Some relevant FAQs on JSP/Servlets can be found at:

 http://java.sun.com/products/jsp/faq.html
 http://www.esperanto.org.nz/jsp/jspfaq.html
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=JSP
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=Servlets

Server-Side Includes

[Chao Chen]

Hi

Does JSWDK-1.0.1 support the SERVLET tag for server-side-include (SSI) ?

CFC

___
To unsubscribe, send email to [EMAIL PROTECTED] and include in the body
of the message "signoff SERVLET-INTEREST".

Archives: http://archives.java.sun.com/archives/servlet-interest.html
Resources: http://java.sun.com/products/servlet/external-resources.html
LISTSERV Help: http://www.lsoft.com/manuals/user/user.html

Does JSWDK-1.0.1 support the SERVLET tag ?

[Chao Chen]

Hi

Does JSWDK-1.0.1 support the SERVLET tag, SERVLET ... /SERVLET,  for
server-side-includes (SSI) ?

CC

___
To unsubscribe, send email to [EMAIL PROTECTED] and include in the body
of the message "signoff SERVLET-INTEREST".

Archives: http://archives.java.sun.com/archives/servlet-interest.html
Resources: http://java.sun.com/products/servlet/external-resources.html
LISTSERV Help: http://www.lsoft.com/manuals/user/user.html

JSP Books

[Chao Chen]

Hi :

I am new to JSP.

Can anyone suggest me a couple of good books??

Regards,
Chen

===
To unsubscribe: mailto [EMAIL PROTECTED] with body: "signoff JSP-INTEREST".
Some relevant FAQs on JSP/Servlets can be found at:

 http://java.sun.com/products/jsp/faq.html
 http://www.esperanto.org.nz/jsp/jspfaq.html
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=JSP
 http://www.jguru.com/jguru/faq/faqpage.jsp?name=Servlets

Re: Installation of JSDK2.0 ?

[Chao Chen]

Baglan:

Thanks a lot.  I sovled the problem based on your suggestions.

Chen

___
To unsubscribe, send email to [EMAIL PROTECTED] and include in the body
of the message "signoff SERVLET-INTEREST".

Archives: http://archives.java.sun.com/archives/servlet-interest.html
Resources: http://java.sun.com/products/servlet/external-resources.html
LISTSERV Help: http://www.lsoft.com/manuals/user/user.html

Instance Variable length For The Array

[Chao Chen]

Hi !

Which class in the Java 2 API Reference can I find the information about the
instance variable "length" for the array object ?  Someone asked me this
question and I just couldn't answer. It is not in the Array class
(java.lang.reflect.Array) when I looked into the reference.

Thanx in advance.
CC

___
To unsubscribe, send email to [EMAIL PROTECTED] and include in the body
of the message "signoff SERVLET-INTEREST".

Archives: http://archives.java.sun.com/archives/servlet-interest.html
Resources: http://java.sun.com/products/servlet/external-resources.html
LISTSERV Help: http://www.lsoft.com/manuals/user/user.html